



Johnson &Johnson







response; Ex19del, exon 19 deletion; HR, hazard ratio; ic, intracranial; MRI, magnetic resonance tomography; NE, not estimable; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.


1. Yang JCH, et al. Presented at: European Lung Cancer Congress (ELCC); March 26–29, 2025; Paris, France. 2. Cho BC, et al. N Engl J Med. 2024;391(16):1486–1498.







Johnson &Johnson



&Johnson

